{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:03Z","timestamp":1740126783638,"version":"3.37.3"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rofo"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>\n            Purpose\u2002To assess serum lactate dehydrogenase (LDH) as a pretreatment prognostic factor in patients with uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion (THC).<\/jats:p><jats:p>\n            Materials and Methods\u200256 patients (48\u200a% male, median age: 63.5 years) underwent a median of 4 THC sessions. Kaplan-Meier for median overall survival (OS) and time to hepatic progression (TTP; 95\u200a%CI) in months and Cox proportional hazards model for uni- (UVA) &amp; multivariate analyses (MVA) for hazard ratio (HR) evaluation were calculated.<\/jats:p><jats:p>\n            Results\u2002The median OS was 9.4 months. The pretreatment LDH value before 1st THC was the strongest OS predictor with 19.8 months for normal (\u2266\u200a280 units per liter (U\/L)), 9.7\u00a0for intermediate (&gt;\u200a280\u2013&lt;\u200a1000\u200aU\/L), and 3.84 months for high (\u2267\u200a1000\u200aU\/L) LDH. LDH significantly predicted a median TTP with 8 months, 4 months, and 1 month for normal, intermediate, and high LDH, respectively. UVA revealed intermediate (16.5) and high (77.3) LDH, bilirubin &gt;\u200athe upper limit of normal (ULN) (2.89), alkaline phosphatase &gt;\u200a1.5 ULN (6.8), leukocytes &gt;\u200aULN (4.2), gamma-glutamyl transferase (GGT) &gt;\u200aULN (7), extrahepatic metastases (1.8) and liver lesions \u2265\u200a5\u200acm (3.6) as significant predictors for worse OS.\u200aMVA confirmed intermediate (5) and high (27.1) LDH, bilirubin (5.7), GGT (2.9), and tumor size \u2265\u200a5\u200acm (3.7) as significant independent predictors for worse OS.\u200aPatients with decreasing vs. increasing LDH &gt;\u200a10\u200a% between 1st and 2nd THC (median: 38 days) survived longer (14.6 vs. 4.3 months) and progressed later (7 months vs. 1 month).<\/jats:p><jats:p>\n            Conclusion\u2002Elevated pretreatment serum LDH is an essential and robust OS and TTP predictor, potentially allowing for the identification of patients benefiting most from transarterial hepatic chemoperfusion.<\/jats:p><jats:p>\n            Key Points:\n          <\/jats:p><jats:p>\n            Citation Format\n          <\/jats:p>","DOI":"10.1055\/a-1299-1627","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T23:59:36Z","timestamp":1608595176000},"page":"683-691","source":"Crossref","is-referenced-by-count":3,"title":["Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in\u00a0Patients with Uveal Melanoma Liver Metastases"],"prefix":"10.1055","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0838-8831","authenticated-orcid":false,"given":"Johannes","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Haubold","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till-Alexander","family":"Heusner","sequence":"additional","affiliation":[{"name":"Clinic for Diagnostic and Interventional Radiology\/Neuroradiology, Sankt-Elisabeth-Hospital G\u00fctersloh, G\u00fctersloh, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"West German Cancer Center, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[{"name":"German Consortium for Translational Cancer Research (DKTK), partner location University Hospital Essen, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Richly","sequence":"additional","affiliation":[{"name":"West German Cancer Center, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Wetter","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-7929","authenticated-orcid":false,"given":"Jens M.","family":"Theysohn","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"R D Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"A D Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"G Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.002","article-title":"Systematic review of liver directed therapy for uveal melanoma hepatic metastases","author":"A Rowcroft","year":"2019","journal-title":"HPB (Oxford)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/JCO.2005.02.6534","article-title":"Variates of survival in metastatic uveal melanoma","volume":"23","author":"P Rietschel","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"S Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"14083","DOI":"10.1007\/s13277-016-5228-2","article-title":"Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU\/L","volume":"37","author":"R Liu","year":"2016","journal-title":"Tumour Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/CMR.0000000000000468","article-title":"Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience","volume":"28","author":"M N Nicholas","year":"2018","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1055\/s-0031-1281743","article-title":"Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment","volume":"183","author":"T A Heusner","year":"2011","journal-title":"Rofo"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"B A Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"M Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"E Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","article-title":"Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis","volume":"21","author":"D Kuk","year":"2016","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ejca.2012.11.032","article-title":"Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy","volume":"49","author":"Y Jin","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2407-11-167","article-title":"Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4","volume":"11","author":"S E Rademakers","year":"2011","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ejca.2011.08.007","article-title":"Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma","volume":"48","author":"F Egberts","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)","volume":"45","author":"S S Agarwala","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semradonc.2004.04.004","article-title":"Lactate: mirror and motor of tumor malignancy","volume":"14","author":"S Walenta","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"L Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10147-017-1095-0","article-title":"Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population","volume":"22","author":"Y Shibayama","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1.3-Bis-(2-Chloroethyl)-1-Nitrosourea","volume":"205","author":"C F Gonsalves","year":"2015","journal-title":"Am J Roentgenol"},{"key":"ref22","first-page":"1897","article-title":"Serum markers to detect metastatic uveal melanoma","volume":"27","author":"V Barak","year":"2007","journal-title":"Anticancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ophtha.2012.01.045","article-title":"Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma","volume":"119","author":"F Mouriaux","year":"2012","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e0120181","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"S Valpione","year":"2015","journal-title":"PLoS\u00a0One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study","volume":"40","author":"T J Vogl","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"I Karydis","year":"2018","journal-title":"J Surg Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"C Artzner","year":"2019","journal-title":"Cancer Imaging"}],"container-title":["R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1299-1627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T22:45:36Z","timestamp":1621550736000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1299-1627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":27,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,5,20]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1299-1627","relation":{},"ISSN":["1438-9029","1438-9010"],"issn-type":[{"type":"print","value":"1438-9029"},{"type":"electronic","value":"1438-9010"}],"subject":[],"published":{"date-parts":[[2020,12,21]]}}}